Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NECVAX-NEO1
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : NEC OncoImmunity
Deal Size : Undisclosed
Deal Type : Acquisition
NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets
Details : Under the agreement, NOI will acquire VAXIMM’s neoantigen vaccine-related patents including VXM01, which is being developed for the treatment of glioblastoma, license the requisite manufacturing patents, and will take over existing contracts with colla...
Product Name : NECVAX-NEO1
Product Type : Vaccine
Upfront Cash : Undisclosed
August 03, 2022
Lead Product(s) : NECVAX-NEO1
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : NEC OncoImmunity
Deal Size : Undisclosed
Deal Type : Acquisition